tiprankstipranks
Trending News
More News >
Bruker Corp (BRKR)
NASDAQ:BRKR
US Market

Bruker (BRKR) Stock Forecast & Price Target

Compare
389 Followers
See the Price Targets and Ratings of:

BRKR Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
6 Buy
5 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Bruker
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BRKR Stock 12 Month Forecast

Average Price Target

$52.78
▲(40.30%Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is $52.78 with a high forecast of $70.00 and a low forecast of $40.00. The average price target represents a 40.30% change from the last price of $37.62.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","44":"$44","53":"$53","62":"$62","71":"$71"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,44,53,62,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.68,39.24307692307692,41.80615384615385,44.36923076923077,46.93230769230769,49.495384615384616,52.058461538461536,54.621538461538464,57.184615384615384,59.747692307692304,62.31076923076923,64.87384615384616,67.43692307692308,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.68,37.918461538461536,39.15692307692308,40.395384615384614,41.63384615384615,42.87230769230769,44.11076923076923,45.34923076923077,46.58769230769231,47.826153846153844,49.06461538461539,50.30307692307692,51.541538461538465,{"y":52.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.68,36.93538461538461,37.19076923076923,37.44615384615385,37.70153846153846,37.956923076923076,38.21230769230769,38.46769230769231,38.723076923076924,38.97846153846154,39.23384615384615,39.48923076923077,39.744615384615386,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.08,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.97,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.54,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.33,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$52.78Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BRKR
TipRanks AITipRanks
Not Ranked
TipRanks
$42
Hold
11.64%
Upside
Reiterated
06/14/25
Bruker's overall score reflects strong financial performance and strategic corporate actions, such as the settlement with 10x Genomics. However, high valuation and potential headwinds from policy changes and tariffs pose risks. Technical indicators suggest limited upside potential in the near term, while earnings call insights highlight both growth and challenges.
Jefferies
$70
Buy
86.07%
Upside
Reiterated
06/04/25
Bruker's Growth Potential Driven by Innovations and Strategic Cost Management
Bank of America Securities Analyst forecast on BRKR
Michael RyskinBank of America Securities
Bank of America Securities
$61
Buy
62.15%
Upside
Reiterated
06/03/25
Bank of America Securities Reaffirms Their Buy Rating on Bruker (BRKR)
Citi
$50$40
Hold
6.33%
Upside
Downgraded
05/23/25
Bruker downgraded to Neutral from Buy at CitiBruker downgraded to Neutral from Buy at Citi
Leerink Partners Analyst forecast on BRKR
Puneet SoudaLeerink Partners
Leerink Partners
Buy
Reiterated
05/13/25
Bruker's Legal Settlement Boosts Investor Confidence and Supports Buy Rating
UBS
$57$45
Hold
19.62%
Upside
Reiterated
05/08/25
Bruker price target lowered to $45 from $57 at UBSBruker price target lowered to $45 from $57 at UBS
J.P. Morgan Analyst forecast on BRKR
Rachel VatnsdalJ.P. Morgan
J.P. Morgan
$60
Buy
59.49%
Upside
Reiterated
05/08/25
J.P. Morgan Keeps Their Buy Rating on Bruker (BRKR)
Stifel Nicolaus Analyst forecast on BRKR
Daniel AriasStifel Nicolaus
Stifel Nicolaus
$57$48
Hold
27.59%
Upside
Reiterated
05/08/25
Stifel Nicolaus Remains a Hold on Bruker (BRKR)
Wells Fargo
$60
Buy
59.49%
Upside
Reiterated
05/07/25
Analysts Offer Insights on Healthcare Companies: Bruker (NASDAQ: BRKR), Qiagen (NYSE: QGEN) and Siemens Healthineers AG (Other OTC: SEMHF)
TD Cowen
$45
Hold
19.62%
Upside
Reiterated
05/07/25
Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties
Barclays Analyst forecast on BRKR
Luke SergottBarclays
Barclays
$50$46
Buy
22.28%
Upside
Reiterated
05/07/25
Bruker (BRKR) PT Lowered to $46 at BarclaysBarclays analyst Luke Sergott lowered the price target on Bruker (NASDAQ: BRKR) to $46.00 (from $50.00) while maintaining a Overweight rating.
Cleveland Research Analyst forecast on BRKR
Unknown AnalystCleveland Research
Not Ranked
Cleveland Research
Hold
Downgraded
04/24/25
Cleveland Research downgrades Bruker (BRKR) to NeutralCleveland Research downgraded Bruker (NASDAQ: BRKR) from Buy to Neutral.
Guggenheim Analyst forecast on BRKR
Subbu NambiGuggenheim
Guggenheim
Buy
Reiterated
02/21/25
Goldman Sachs Analyst forecast on BRKR
Matthew SykesGoldman Sachs
Goldman Sachs
Hold
Upgraded
12/05/24
Goldman Sachs upgrades Bruker (BRKR) to NeutralGoldman Sachs analyst Matthew Sykes upgraded Bruker (NASDAQ: BRKR) from Sell to Neutral with a price target of $60.00.
Wolfe Research Analyst forecast on BRKR
Doug SchenkelWolfe Research
Wolfe Research
Hold
Downgraded
09/30/24
Bruker (BRKR) was downgraded to a Hold Rating at Wolfe Research
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BRKR
TipRanks AITipRanks
Not Ranked
TipRanks
$42
Hold
11.64%
Upside
Reiterated
06/14/25
Bruker's overall score reflects strong financial performance and strategic corporate actions, such as the settlement with 10x Genomics. However, high valuation and potential headwinds from policy changes and tariffs pose risks. Technical indicators suggest limited upside potential in the near term, while earnings call insights highlight both growth and challenges.
Jefferies
$70
Buy
86.07%
Upside
Reiterated
06/04/25
Bruker's Growth Potential Driven by Innovations and Strategic Cost Management
Bank of America Securities Analyst forecast on BRKR
Michael RyskinBank of America Securities
Bank of America Securities
$61
Buy
62.15%
Upside
Reiterated
06/03/25
Bank of America Securities Reaffirms Their Buy Rating on Bruker (BRKR)
Citi
$50$40
Hold
6.33%
Upside
Downgraded
05/23/25
Bruker downgraded to Neutral from Buy at CitiBruker downgraded to Neutral from Buy at Citi
Leerink Partners Analyst forecast on BRKR
Puneet SoudaLeerink Partners
Leerink Partners
Buy
Reiterated
05/13/25
Bruker's Legal Settlement Boosts Investor Confidence and Supports Buy Rating
UBS
$57$45
Hold
19.62%
Upside
Reiterated
05/08/25
Bruker price target lowered to $45 from $57 at UBSBruker price target lowered to $45 from $57 at UBS
J.P. Morgan Analyst forecast on BRKR
Rachel VatnsdalJ.P. Morgan
J.P. Morgan
$60
Buy
59.49%
Upside
Reiterated
05/08/25
J.P. Morgan Keeps Their Buy Rating on Bruker (BRKR)
Stifel Nicolaus Analyst forecast on BRKR
Daniel AriasStifel Nicolaus
Stifel Nicolaus
$57$48
Hold
27.59%
Upside
Reiterated
05/08/25
Stifel Nicolaus Remains a Hold on Bruker (BRKR)
Wells Fargo
$60
Buy
59.49%
Upside
Reiterated
05/07/25
Analysts Offer Insights on Healthcare Companies: Bruker (NASDAQ: BRKR), Qiagen (NYSE: QGEN) and Siemens Healthineers AG (Other OTC: SEMHF)
TD Cowen
$45
Hold
19.62%
Upside
Reiterated
05/07/25
Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties
Barclays Analyst forecast on BRKR
Luke SergottBarclays
Barclays
$50$46
Buy
22.28%
Upside
Reiterated
05/07/25
Bruker (BRKR) PT Lowered to $46 at BarclaysBarclays analyst Luke Sergott lowered the price target on Bruker (NASDAQ: BRKR) to $46.00 (from $50.00) while maintaining a Overweight rating.
Cleveland Research Analyst forecast on BRKR
Unknown AnalystCleveland Research
Not Ranked
Cleveland Research
Hold
Downgraded
04/24/25
Cleveland Research downgrades Bruker (BRKR) to NeutralCleveland Research downgraded Bruker (NASDAQ: BRKR) from Buy to Neutral.
Guggenheim Analyst forecast on BRKR
Subbu NambiGuggenheim
Guggenheim
Buy
Reiterated
02/21/25
Goldman Sachs Analyst forecast on BRKR
Matthew SykesGoldman Sachs
Goldman Sachs
Hold
Upgraded
12/05/24
Goldman Sachs upgrades Bruker (BRKR) to NeutralGoldman Sachs analyst Matthew Sykes upgraded Bruker (NASDAQ: BRKR) from Sell to Neutral with a price target of $60.00.
Wolfe Research Analyst forecast on BRKR
Doug SchenkelWolfe Research
Wolfe Research
Hold
Downgraded
09/30/24
Bruker (BRKR) was downgraded to a Hold Rating at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bruker

1 Month
xxx
Success Rate
14/31 ratings generated profit
45%
Average Return
+0.03%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.16% of your transactions generating a profit, with an average return of +0.03% per trade.
3 Months
xxx
Success Rate
12/31 ratings generated profit
39%
Average Return
-3.77%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.71% of your transactions generating a profit, with an average return of -3.77% per trade.
1 Year
Success Rate
16/31 ratings generated profit
52%
Average Return
+2.10%
reiterated a buy rating last month
Copying Brandon Couillard's trades and holding each position for 1 Year would result in 51.61% of your transactions generating a profit, with an average return of +2.10% per trade.
2 Years
xxx
Success Rate
20/31 ratings generated profit
65%
Average Return
+9.11%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.52% of your transactions generating a profit, with an average return of +9.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BRKR Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
5
6
9
6
6
Buy
14
12
10
10
10
Hold
5
3
4
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
21
23
22
22
In the current month, BRKR has received 16 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. BRKR average Analyst price target in the past 3 months is 52.78.
Each month's total comprises the sum of three months' worth of ratings.

BRKR Financial Forecast

BRKR Earnings Forecast

Next quarter’s earnings estimate for BRKR is $0.44 with a range of $0.37 to $0.53. The previous quarter’s EPS was $0.47. BRKR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.
Next quarter’s earnings estimate for BRKR is $0.44 with a range of $0.37 to $0.53. The previous quarter’s EPS was $0.47. BRKR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.

BRKR Sales Forecast

Next quarter’s sales forecast for BRKR is $812.95M with a range of $805.00M to $834.30M. The previous quarter’s sales results were $801.40M. BRKR beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.
Next quarter’s sales forecast for BRKR is $812.95M with a range of $805.00M to $834.30M. The previous quarter’s sales results were $801.40M. BRKR beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.

BRKR Stock Forecast FAQ

What is BRKR’s average 12-month price target, according to analysts?
Based on analyst ratings, Bruker Corp’s 12-month average price target is 52.78.
    What is BRKR’s upside potential, based on the analysts’ average price target?
    Bruker Corp has 40.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BRKR a Buy, Sell or Hold?
          Bruker Corp has a consensus rating of Moderate Buy which is based on 6 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Bruker Corp’s price target?
            The average price target for Bruker Corp is 52.78. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $40.00. The average price target represents 40.30% Increase from the current price of $37.62.
              What do analysts say about Bruker Corp?
              Bruker Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of BRKR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis